Roles of Individual Institutions in Achieving Pharmaceutical Sovereignty as Exemplified by the Medical Technology Transfer Centre of the Scientific Centre for Expert Evaluation of Medicinal Products

INTRODUCTION. The strengthening of the health system and the improvement of access to medicines directly depend on the development and marketing authorisation of national innovative medicinal products. Technology transfer is a key tool in bringing medicinal products to market.

AIM. This study aimed to evaluate the role of the Medical Technology Transfer Centre of the Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’) in facilitating the implementation of federal projects in medical science and in achieving of pharmaceutical sovereignty.

DISCUSSION. This article is an overview of the main trends in and features of the development of the pharmaceutical industry in the Russian Federation and around the world. The article highlights significant federal decisions made to attain pharmaceutical sovereignty and improve access to medicines for the population. The authors consider documents regulating the work of the Medical Technology Transfer Centre and outline its roles and responsibilities. Additionally, the authors analyse the ability of the Medical Technology Transfer Centre to provide project support throughout the medicinal product development process and to address issues pertaining to efficient pharmaceutical development, patent law, and product commercialisation. The article assesses the role of the Medical Technology Transfer Centre in the development of the pharmaceutical industry in the Russian Federation.

CONCLUSIONS. The Medical Technology Transfer Centre supports projects as part of efforts to implement federal projects in human medical science. The Medical Technology Transfer Centre can be considered a driver of effective innovative development in the national pharmaceutical industry.

1. Dremova NB, Solomka SV. World pharmaceutical market: trendwatching. Laboratory and Clinical Medicine. Pharmacy. 2022;2(1):56–68 (In Russ.). https://doi.org/10.14489/lcmp.2022.01.pp.056-068

2. Romanova OV, Avrutskaya SG. Digital trends in the pharmaceutical industry during the COVID-19 pandemic. Advances in Chemistry and Chemical Technology. 2021;35(1):59–61 (In Russ.). EDN: RSKKLJ

3. Dolgopolov IS, Rykov MYu. The evolution of personalized medicine: literature review. Research’n Practical Medicine Journal. 2022;9(3):117–28 (In Russ.). https://doi.org/10.17709/2410-1893-2022-9-3-9

4. Golubev AM. Personalized critical care medicine (review). General Reanimatology. 2022;18(4):45–54 (In Russ.). https://doi.org/10.15360/1813-9779-2022-4-45-54

5. Abaimov DA, Fedotova EYu, Poleshchuk VV, Andreev MN, Trifonova OP, Lokhov PG, Illarioshkin SN. Principles of personalized medicine and modern pharmaceutical technologies in optimizing levodopa therapy of Parkinson’s disease. Annals of Clinical and Experimental Neurology. 2021;15(2):73–82 (In Russ.). https://doi.org/10.25692/ACEN.2021.2.9

6. Shlyakhto EV, Konradi AO. Personalized medicine. History, current state and future directions. Russian Journal for Personalized Medicine. 2021;1(1):6–20 (In Russ.). EDN: ISXQRM

7. Mokrysheva NG, Melnichenko GA. Personalized medicine — stages of concept formation and ways of its practical implementation. Russian Journal for Personalized Medicine. 2021;1(1):43–58 (In Russ.). EDN: FMLQUG

8. Tkachenko SN, Tkachenko IS, Egorova AI. Strategizing of the chemical industry. In: Theory and practice of strategizing. Moscow; 2021. P. 94–8 (In Russ.). EDN: AGOALW

9. Chernysheva АМ, Zobov АМ, Fedorenko ЕА. Analysis of the development strategy of the pharmaceutical industry in the Russian Federation for the period up to 2030 and sustainable development metrics for strategic alliances of the pharmaceutical industry. Bulletin of the Academy of Knowledge. 2021;46(5):338–47 (In Russ.). https://doi.org/10.24412/2304-6139-2021-5-338-347

10. Kostin KB, Shanava LA. Key trends in the development of the Russian pharmaceutical market amidst uncertainty. Economics, Entrepreneurship and Law. 2022;12(5):1639–58 (In Russ.). https://doi.org/10.18334/epp.12.5.114635

11. Matveeva AV. To the question of designing innovation in the pharmaceutical industry. Naučnye Gorizonty. 2021;(6):19–29 (In Russ.). EDN: FWJOWK

12. Prozherina Yu. Global pharma market 2021 trends. Remedium. 2021;(1):9–11 (In Russ.). https://doi.org/10.21518/1561-5936-2021-1-9-11

13. Spirin NN, Vlasov YaV, Zakharova MN, Khachanova NV, Popova EV, Khabirov FA, et al. New opportunities in the treatment of patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7–2):84–8 (In Russ.). https://doi.org/10.17116/jnevro202212207284

14. Unku LV, Chobanu NT, Valika VV. Prospects for the development of combined preparations for the pharmacotherapy of certain ear diseases. In: Current technologies in medical education. Minsk; 2021 (In Russ.). EDN: VHADSV

15. Polkovnikova YuA, Gusсhina OS. Prospects for the development of solid dispersed antibiotic systems (scoping review). Health, Food & Biotechnology. 2022;4(1):24–33 (In Russ.). https://doi.org/10.36107/hfb.2022.i1.s129

16. Morozkina SN, Olekhnovich RO, Snetkov PP. Some natural bioactive compounds and their delivery systems based on hyaluronic acid. Saint Petersburg: ITMO; 2021 (In Russ.). EDN: XYBOCV

17. Gegirova AKh. Innovative dosage forms. Trends in the Development of Science and Education. 2022;(81–6):5–7 (In Russ.). https://doi.org/10.18411/trnio-01-2022-206

18. Karnysheva NG, Kudinova LV. New dosage forms. In: Problems of modern integration processes and ways to solve them. Sterlitamak; 2021. P. 104–15 (In Russ.). EDN: LDZUOF

19. Karimova AF, Merkurieva GYu, Kamaeva SS. Liposomes — a prospective system for delivery of medical substances. In: Problems and trends of scientific transformation under the conditions of social transformations. Sterlitamak; 2021. P. 172 (In Russ.). EDN: XEJJHJ

20. Nechaeva Yu. Import of pharmaceutical substances to Russia in 2020. Remedium. 2021;(2):32–5 (In Russ.). https://doi.org/10.21518/1561-5936-2021-2-32-35

21. Dorzhieva VV. Strategy of new industrialization of the pharmaceutical industry: national priorities and new challenges. Scientific Works of the Free Economic Society of Russia. 2023:240(2):198–215 (In Russ.). https://doi.org/10.38197/2072-2060-2023-240-2-198-215

22. Gusev AB, Yurevich MA. The sovereignty of Russia in the area of pharmaceuticals: Challenges and opportunities. Terra Economicus. 2023:21(3):17–31 (In Russ.). https://doi.org/10.18522/2073-6606-2023-21-3-17-31

23. Shakhnovich ОА. Low-tonnage chemistry of Russia: history and prospects. Laboratoriâ i Proizvodstvo. 2023;(3–4):24–38 (In Russ.). EDN: HKBKBI

24. Vasilevich NI. Active pharmaceutical ingredients are the main condition for the innovative development of Russian pharmaceuticals. Laboratoriâ i Proizvodstvo. 2021;(1):30–40 (In Russ.). EDN: PCDMUM